MedTrace Logo

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

NCT02230878 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2017-01-24

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety, tolerability, pharmacokinetic (the study of the way a drug enters and leaves the blood and tissues over time), dose-proportionality, accumulation, urinary excretion, pharmacodynamics (the study of how drugs act on the body) and sedative effects of JNJ-42847922 in healthy male and female participants.

Conditions

  • Healthy

Interventions

DRUG

JNJ-42847922 5 mg

Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.

DRUG

JNJ-42847922 10 mg

Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.

DRUG

JNJ-42847922 20 mg

Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.

DRUG

JNJ-42847922 40 mg

Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .

DRUG

Placebo

Participants will receive matching placebo from Day 1 up to Day 10.

Sponsors & Collaborators

  • Janssen-Cilag International NV

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag International NV Clinical Trial · Janssen-Cilag International NV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02230878 on ClinicalTrials.gov